Overcoming Nursing Management Challenges in Metastatic Castration-Resistant Prostate Cancer

STATEMENT OF NEED

Prostate cancer is the most common tumor type affecting men in the United States. An estimated 268,490 new cases are diagnosed annually, and 34,500 people die of the disease (ACS, 2022). Typically, androgen deprivation therapy (ADT) is administered for progressive disease. However, castration resistance or unresponsiveness to ADT or antiandrogens frequently develop over time. Nonmetastatic castration-resistant prostate cancer (CRPC) is a highly heterogeneous disease process with limited effective treatment options. Metastatic CRPC is the primary cause of prostate cancer-related mortality and is associated with a median overall survival of less than 2 years (Seyegh et al, 2022). Therefore, it is critical for oncology nurses and others involved in the care of patients with prostate cancer to maintain up-to-date knowledge about CRPC therapies and supportive care. In this activity, Kathy Burns, MSN, ANP, OCN®, will discuss various topics relevant to the treatment of metastatic CRPC, including diagnosis, staging, and the latest clinical trial results. She will also highlight the management of drug interactions and adverse events related to novel therapies.

TARGET AUDIENCE

Oncology nurses, nurse practitioners, clinical nurse specialists, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

Evaluate the diagnosis and staging of metastatic CRPC
Appraise the efficacy and safety profiles of novel therapies for metastatic CRPC as elucidated by recent clinical trials
Devise strategies to manage drug interactions and adverse events associated with novel therapies for metastatic CRPC